FLUIDIC	SM CORF
Form SC	13G/A
February	13, 2017

UNITED STATES	
SECURITIES AND EXC Washington, DC 20549	CHANGE COMMISSION

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

Fluidigm Corporation (Name of Issuer)

Common Stock

(Title of Class of Securities)

34385P108 (CUSIP Number)

December 31, 2016 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

x Rule 13d-1(b)

o Rule 13d-1(c)

o Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 2 of 9 Pages

SCHEDULE 13G/A

CUSIP No. 34385P108

IA

NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) 1 OrbiMed Advisors LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 2 (a) o (b) o SEC USE ONLY 3 CITIZENSHIP OR PLACE OF ORGANIZATION 4 Delaware SOLE VOTING POWER 5 NUMBER OF 0 **SHARES** SHARED VOTING POWER **BENEFICIALLY** 6 OWNED BY 361.842 **EACH REPORTING** SOLE DISPOSITIVE POWER **PERSON** 7 WITH SHARED DISPOSITIVE POWER 8 361,842 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 361,842 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN o SHARES (See Instructions) 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 1.24%* TYPE OF REPORTING PERSON (See Instructions) 12

* This percentage is based upon 29,118,140 shares outstanding as of October 28, 2016, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 8, 2016 and includes 79,830 shares issuable upon the exercise of convertible securities.

CUSIP No. 34385P108 Page 3 of 9 Pages SCHEDULE 13G/A NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) 1 OrbiMed Capital LLC CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 2 (a) o (b) o SEC USE ONLY 3 CITIZENSHIP OR PLACE OF ORGANIZATION 4 Delaware **SOLE VOTING POWER** 5 NUMBER OF 0 **SHARES** SHARED VOTING POWER **BENEFICIALLY** 6 **OWNED BY** 1,695,019 **EACH** SOLE DISPOSITIVE POWER **REPORTING** 7 **PERSON** 0 WITH SHARED DISPOSITIVE POWER 8 1,695,019 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 1,695,019 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN o SHARES (See Instructions) 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 5.80%*

TYPE OF REPORTING PERSON (See Instructions)

12

ΙA

^{*} This percentage is based upon 29,118,140 shares outstanding as of October 28, 2016, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 8, 2016 and includes 98,920 shares issuable upon the exercise of convertible securities.

Page 4 of 9 Pages

SCHEDULE 13G/A

CUSIP No. 34385P108

NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) 1 Samuel D. Isaly CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 2 (a) o (b) o SEC USE ONLY 3 CITIZENSHIP OR PLACE OF ORGANIZATION 4 **United States** SOLE VOTING POWER 5 NUMBER OF 0 **SHARES** SHARED VOTING POWER **BENEFICIALLY** 6 OWNED BY 2,056,861 **EACH REPORTING** SOLE DISPOSITIVE POWER **PERSON** 7 WITH SHARED DISPOSITIVE POWER 8 2,056,861 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9 2,056,861 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN o SHARES (See Instructions) 10 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11 7.02%* TYPE OF REPORTING PERSON (See Instructions) 12 HC

* This percentage is based upon 29,118,140 shares outstanding as of October 28, 2016, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 8, 2016 and includes 178,750 shares issuable upon the exercise of convertible securities.

CUSIP No. 34385P108	SCHEDULE 13G/A	Page 5 of 9 Pages	
Item 1. (a) Name of Issuer:			
Fluidigm Corporation			
	(b) Address of Issuer's Prin	ncipal Executive Offices:	
7000 Shoreline Court, Suite 100			
South San Francisco, CA 94080			
Item 2.	(a) Name	e of Person Filing:	
OrbiMed Advisors LLC			
OrbiMed Capital LLC			
Samuel D. Isaly			
	(b) Address of Princi	ipal Business Office:	
601 Lexington Avenue, 54th Floor			
New York, NY 10022			
	(c)	Citizenship:	
Please refer to Item 4 on each cover sheet for each filing person.			
	(d) Title of Cl	lass of Securities:	
Common Stock			
	(e)	CUSIP No.:	
34385P108			

CUSIP No. 34385P108

SCHEDULE 13G/A

Page 6 of 9 Pages

Item 3. OrbiMed Advisors LLC and OrbiMed Capital LLC are investment advisors in accordance with ss.240.13d-1(b)(1)(ii)(E). Samuel D. Isaly is a control person in accordance with ss.240.13d-1(b)(1)(ii)(G).

CUSIP No. 34385P108	SCHEDULE 13G/A	Page 7 of 9 Pages
Item 4. Ownership:		
Please see Items 5 - 9 and 11 fo	or each cover sheet for each filing.	
Item 5. Ownership of Five P	ercent or Less of a Class.	
Not Applicable.		
Item 6. Ownership of More	Than Five Percent on Behalf of Anotl	ner Person.
OrbiMed Capital LLC) of the s receipt of dividends from, or pr	hares on behalf of other persons who ha	Advisors LLC and 5.80% in the case of ave the right to receive or the power to direct the s. No one such other person's interest in the percent of the class.
Item 7. Identification and Cla the Parent Holding Company	_	cquired the Security Being Reported on by
Not Applicable.		
Item 8. Identification and Cla	ssification of Members of the Group	
Not Applicable.		
Item 9. Notice of Dissolution	of Group.	
Not Applicable.		
Item 10. Certification.		
By signing below I certify that,	to the best of my knowledge and belief	f, the securities referred to above were acquired

and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect

of changing or influencing the control of the issuer of the securities and were not acquired and are not held in

connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 34385P108

SCHEDULE 13G/A

Page 8 of 9 Pages

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 13, 2017

OrbiMed Advisors LLC

By: Samuel D. Isaly

Name: Samuel D. Isaly Title: Managing Member

OrbiMed Capital LLC

By: Samuel D. Isaly

Name: Samuel D. Isaly Title: Managing Member CUSIP No. 34385P108

SCHEDULE 13G/A

Page 9 of 9 Pages

EXHIBIT A

JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on this Schedule 13G/A dated February 13, 2017 (the "Schedule 13G/A"), with respect to the Common Stock, par value \$0.001 per share, of Fluidigm Corporation is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of February 13, 2017.

OrbiMed Advisors LLC

By: Samuel D. Isaly

Name: Samuel D. Isaly Title: Managing Member

OrbiMed Capital LLC

By: Samuel D. Isaly

Name: Samuel D. Isaly Title: Managing Member

The Statement on this Schedule 13G/A dated February 13, 2017 with respect to the Common Stock of Fluidigm Corporation is filed by Samuel D. Isaly in accordance with the provisions of Rule 13d-1(b) and Rule 13d-1(k), respectively, as control person (HC) of OrbiMed Advisors LLC and OrbiMed Capital LLC.

OrbiMed Advisors LLC and OrbiMed Capital LLC file this statement on Schedule 13G/A in accordance with the provisions of Rule 13d-1(b) and Rule 13d-1(k), respectively, as investment advisors (IA).